Frequency of coronary artery stenosis in patients with asymptomatic familial hypercholesterolemia and its association with carotid intimal thickness and cardio-ankle vascular index

Masayo Suzuki1
Mao Takahashi1
Takuo Iizuka1
Hitoshi Terada2
Hirohumi Noike1
Kohji Shirai3

1Cardiovascular Center, Internal Medicine, 2Department of Radiology, 3Department of Vascular Function, Sakura Hospital, Medical Center, Toho University, Sakura City, Chiba Prefecture, Japan

Background: Familial hypercholesterolemia (FH) is associated with premature coronary arterial disease. We aimed to determine the incidence of coronary artery stenosis (CAS) in asymptomatic FH patients using coronary computed tomography angiography (CCTA). To investigate the association between CAS and atherosclerosis of carotid arteries, we performed ultrasonography to measure the mean intima-media thickness (IMT), maximum IMT, and plaque score. We also aimed to examine the significance of the cardio-ankle vascular index (CAVI) and its association with the incidence of CAS in asymptomatic FH patients.

Patients and methods: We enrolled consecutively, 31 FH patients without symptoms of coronary artery disease. Based on the CCTA findings, we divided the patients into two groups, those with and without CAS, and compared various parameters and risk factors of the two groups.

Results: Of 31 FH patients, seven patients (22.6%) had CAS. The proportion of male patients and mean low-density lipoprotein-cholesterol level were higher in patients with CAS than in those without CAS (P = 0.05). All carotid ultrasonography parameters (ie, mean IMT, maximum IMT, and plaque score) were significantly higher in patients with CAS than in those without CAS (P < 0.01), whereas no significant difference was found in CAVI between the two groups.

Conclusion: CAS was identified in 22.6% of the asymptomatic FH patients. Patients with CAS tended to have enhanced levels of carotid plaque markers, but no increase was noted in CAVI. FH patients should be continuously monitored using CCTA and ultrasonography.

Keywords: CAVI, coronary artery stenosis, heterozygous familial hypercholesterolemia, CCTA, ultrasound evaluation of the carotid artery

Introduction

Familial hypercholesterolemia (FH) is characterized by markedly elevated low-density lipoprotein (LDL)-cholesterol levels and premature coronary artery disease.1–3 The known hereditary mutant alleles are LDL-receptor, apolipoprotein B-100, and PCSK9 genes.4 The prevalence of heterozygous FH is reported to be one in 500 in the general population.5 Although coronary angiographical studies are recommended in FH patients to monitor premature coronary arterial disease,6,7 in clinical practice, it is often difficult to perform such invasive studies in asymptomatic FH patients. The recent advancement in multislice computed tomography (MSCT) imaging technology that demonstrates coronary artery imaging using a 64-slice MSCT scanner allows a less-invasive means of assessment.8,9 In the present study, we performed coronary computed tomography angiography (CCTA) with a 64-slice scanner to determine the frequency of coronary...
artery stenosis (CAS) in asymptomatic FH patients (ie, who had no coronary symptoms and no known coronary artery disease).

Because atherosclerosis is a systemic arterial disease, coronary atherosclerosis is associated with arteriosclerosis of the carotid artery as well as that of the aorta and femoral and tibial arteries. Therefore, in the present study, we also aimed to investigate the association between CAS and carotid atherosclerosis in asymptomatic FH patients. We performed B-mode (two dimensional) arterial ultrasonography, a non-invasive method to evaluate the extent of atherosclerosis in carotid arteries and to measure the mean intima-media thickness (IMT), maximum IMT, and plaque score (PS), which are known markers of carotid atherosclerosis.

Furthermore, we measured the cardio-ankle vascular index (CAVI) to evaluate arterial stiffness in asymptomatic FH patients, as it is another marker of atherosclerosis. As a noninvasive method to assess arterial stiffness, pulse wave velocity (PWV) has long been used as an established marker. In particular, carotid-femoral PWV is a useful predictor of coronary artery diseases in arteriosclerotic patients. However, PWV has been found to be altered by blood pressure (BP) at the time of measurement. Against this background, CAVI was developed as a more reliable marker of atherosclerosis. CAVI, which represents the stiffness of the artery from the origin of the aorta to the ankle, is derived from the stiffness parameter beta theory of Hayashi et al. CAVI has been shown to be independent of BP at the time of measurement. Several clinical studies have shown that CAVI is increased in patients with CAS, chronic kidney disease, severe diabetes mellitus, and hypertension; those on hemodialysis; and smokers. CAVI is considered to be an excellent surrogate marker of general atherosclerosis. Nevertheless, the predictive ability of CAVI for coronary artery disease in FH patients has not yet been fully investigated. Although it is reported that CAVI is not elevated in FH patients, hypercholesterolemia is associated with CAVI. Therefore, in the present study, we aimed to determine whether CAVI could be a predictor of coronary atherosclerosis in asymptomatic FH patients.

Patients and methods

Patients

We used data from 31 consecutive FH patients without symptoms of angina who were diagnosed as having FH at our department during the period between September 2007 and September 2011, according to the criteria proposed by the research group on primary hyperlipoproteinemia in the Ministry of Welfare and Labour of Japan. The patients were admitted with suspected coronary artery disease because FH is known to have severe coronary atherosclerosis. Briefly, the criteria are total cholesterol level >230 mg/dL, Achilles tendon thickness >9 mm, and a familial history of hypercholesterolemia.

Based on the findings of CCTA, we identified patients with CAS (CAS group) and compared them with those without CAS (non-CAS group) to determine risk factors for the incidence of CAS in asymptomatic FH patients.

This study was designed and monitored in accordance with the ethics and principles of Good Clinical Practice and the Declaration of Helsinki. This study was approved by the institutional review board of Toho University Sakura Medical Center. Before participation, the purpose of this study was explained to each patient, and all participants gave written informed consent.

Computed coronary tomographic angiography

Multislice CCTA was performed using Aquilion 64-slice scanner (Toshiba Co., Tokyo, Japan). The CCTA data were analyzed on a three-dimensional workstation (ZIO M900 QUADRA; Amin Co., Ltd., Tokyo, Japan). Metoprolol 20–60 mg was administered as the premedication to decrease the pulse rate to 50–70 pulses/min. Each patient's heart was controlled under sinus rhythm. Scan protocol was performed according to prospective gating methods with 120 kV×200 mA. The angiographic agent, iopamidol-370 (body weight ×0.05 mL/sec), was administered through the brachial medial vein. Scans were analyzed by consensus of two observers unaware of the clinical data. Luminal narrowing of ≥50% on CCTA at the worst view position indicated CAS. The 15-segment American Heart Association model of the coronary tree was used. Each lesion identified was examined using maximum intensity and multiplanar reconstruction techniques along multiple longitudinal axes and also transversely. Plaque with calcification was defined as >130 Hounsfield unit (HU) with 3 mm length, and noncalcified plaque was defined as <120 HU.

Ultrasound evaluation of the carotid artery

Ultrasound evaluation of the common carotid artery was performed with high-resolution ultrasonography (Toshiba Co.) using a 7.5 MHz probe equipped with a Doppler system. After the patient had rested in the supine position, the neck was slightly hyperextended and optimal bilateral visualization of the carotid arteries was performed according...
Cardioankle vascular index

CAVI was measured using VaSera1500 (Fukuda Denshi Co. Ltd., Tokyo, Japan). Examinations were performed after resting for 10 minutes. The measurement method was described previously. Briefly, CAVI is calculated by applying BP and PWV to the following formula: 

\[
CAVI = a \cdot \left( \left( \frac{2 \rho \Delta P}{\rho} \right) \times \ln \left( \frac{P_s}{P_d} \right) \right) + b
\]

where \( P_s \) is systolic BP, \( P_d \) is diastolic BP, PWV is pulse wave velocity, \( \Delta P \) is \( P_s - P_d \), \( \rho \) is blood density, and \( a \) and \( b \) are constants. The brachial and ankle pulse waves were determined using inflatable cuffs with the pressure maintained between 30 mmHg and 50 mmHg to ensure that the cuff pressure had a minimal effect on the systemic hemodynamics. BP and pulse pressure were determined simultaneously.

Blood sample collection

Blood samples were collected from the antecubital vein in the morning after 12 hours of fasting. To measure hemoglobin A1c (HbA1c), blood was collected in tubes containing ethylenediaminetetraacetic acid. The stable and unstable fractions of HbA1c were measured by high-pressure liquid chromatography (Hi-Auto A1c analyzer system; Kyoto Daiichi Kagaku, Kyoto, Japan). Stable form data were used in the present analysis. HbA1c was expressed as the value determined by the National Glycohemoglobin Standardization Program.

Plasma total cholesterol and triglyceride levels were measured enzymatically using kits from Nippon Shoji Co., Ltd. (Osaka, Japan) and a 7150 analyzer (Hitachi Ltd., Tokyo, Japan). Serum high-density lipoprotein cholesterol was measured using a selective inhibition assay (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan). Serum LDL cholesterol levels were calculated using the Friedewald formula.

Definition of risk factors

Diabetes mellitus was defined according to the World Health Organization criteria and/or as having received treatment for diabetes mellitus. Dyslipidemia was defined as a total cholesterol concentration ≥220 mg/dL, a triglyceride concentration ≥150 mg/dL, and/or having received treatment for dyslipidemia. Hypertension was defined as systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg, and/or having received treatment for hypertension.

Statistical analysis

Statistical analysis was performed using SPSS Version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Quantitative data were expressed as mean value ± SD. Qualitative variables were presented by the frequency and percentage. The comparison between CAS and non-CAS groups was performed using the Mann–Whitney U test. Qualitative variables were presented by the exact model. These risk factors were scored as explanatory factors, and the subordinate variables were CAS = 1 and non-CAS = 0. The receiver operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of potential parameters used for diagnosis of CAS. A two-tailed \( P \)-value of <0.05 was considered statistically significant.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patient characteristics (N=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor</td>
<td>Total (N=31)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61±12</td>
</tr>
<tr>
<td>Men, % (n)</td>
<td>25.8 (8)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.6±2.6</td>
</tr>
<tr>
<td>Hypertension, % (n)</td>
<td>35.5 (11)</td>
</tr>
<tr>
<td>Diabetes mellitus, % (n)</td>
<td>29.0 (9)</td>
</tr>
<tr>
<td>Smoking, % (n)</td>
<td>25.8 (8)</td>
</tr>
<tr>
<td>Family history of CAD, % (n)</td>
<td>25.8 (8)</td>
</tr>
<tr>
<td>Treatment of hypercholesterolemia, % (n)</td>
<td>87.1 (27)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.9±0.9</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>237.4±57.6</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>55.1±13.7</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>154.0±56.5</td>
</tr>
<tr>
<td>LDL-C/HDL-C ratio</td>
<td>3.0±1.6</td>
</tr>
<tr>
<td>Chest pain, % (n)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Note: Values are expressed as mean ± SD or % (n).

Abbreviations: BMI, body mass index; CAD, coronary artery disease; HbA1c, hemoglobin A1c; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Results

Patient characteristics

Table 1 shows the characteristics of patients, including serum profiles and medical treatment. The majority of patients were women. Approximately one-third of the patients had diabetes mellitus and more than one-third had hypertension. The mean total cholesterol was 237.4 mg/dL, and most patients were receiving treatment for hypercholesterolemia.

Findings from CCTA, ultrasonography, and CAVI

Table 2 shows the findings from CCTA, ultrasonography, and CAVI in 31 patients. The CCTA revealed that seven patients (22.6%) had CAS, two patients had one affected vessel, and five patients had two affected vessels. Coronary calcified plaque was found in 19 (61.3%) patients.

Comparisons of risk factors between the CAS group and non-CAS group

Risk factors

There was no significant difference in the mean age between the CAS group and non-CAS group. There were more male patients in the CAS group than in the non-CAS group. HbA1c was slightly higher in the CAS group than in the non-CAS group, but the difference was not significant. In both groups, most patients had received treatment with lipid-lowering agents; statins were most commonly taken in both groups, followed by ezetimibe and probucol. Although all patients in the CAS group were under lipid-lowering treatment, LDL-C was slightly higher in the CAS group than in the non-CAS group. HbA1c, the mean age, and the mean total cholesterol were higher in the CAS group than in the non-CAS group. There were more male patients and a higher proportion of patients with hypertension in the CAS group compared with the non-CAS group (Table 3).

Carotid arteriosclerotic findings

Mean IMT, maximum IMT, and PS were significantly higher in the CAS group than in the non-CAS group (Table 3).

CAVI

There was a significant correlation between age and CAVI (Figure 1). However, CAVI was not significantly higher in the CAS group compared with the non-CAS group (Table 3).

ROC curve analysis in patients with CAS

The ROC curve analysis was performed to determine cutoff values of various parameters (mean IMT, PS, and CAVI) based on the proportion of true-positive results (sensitivity) and false-positive results (1-specificity) to determine the probability of CAS in FH patients (Figure 2). The cutoff values of mean IMT and PS that gave the maximum sensitivity and specificity for CAS were 0.82 mm and 5.1 mm, respectively. At the cutoff level, the sensitivities of mean IMT and PS for CAS were 75%, and 87.5%, respectively, and the specificities were 85.7% and 78.6%, respectively.

Table 3 Comparison of cardiovascular risk factors between CAS and non-CAS groups

<table>
<thead>
<tr>
<th>Factor</th>
<th>CAS (n=7)</th>
<th>Non-CAS (n=24)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63±14</td>
<td>60±11</td>
<td>0.44&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Men, % (n)</td>
<td>57.1 (4)</td>
<td>16.7 (4)</td>
<td>0.03&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.7±1.4</td>
<td>22.6±1.8</td>
<td>0.98&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hypertension, % (n)</td>
<td>57.1 (4)</td>
<td>29.2 (7)</td>
<td>0.19&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetes mellitus, % (n)</td>
<td>57.1 (4)</td>
<td>20.8 (5)</td>
<td>0.07&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>28.6 (2)</td>
<td>25.0 (6)</td>
<td>0.86&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Family history of CAD, % (n)</td>
<td>42.9 (3)</td>
<td>20.8 (5)</td>
<td>0.78&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Antilipidemic treatment, % (n)</td>
<td>100 (7)</td>
<td>83.3 (20)</td>
<td>0.26&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Statin, % (n)</td>
<td>71.4 (5)</td>
<td>79.1 (19)</td>
<td></td>
</tr>
<tr>
<td>Probiotic, % (n)</td>
<td>14.2 (1)</td>
<td>16.7 (4)</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe, % (n)</td>
<td>28.6 (2)</td>
<td>20.8 (5)</td>
<td></td>
</tr>
<tr>
<td>Fibrate, % (n)</td>
<td>14.2 (1)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Colestimide, % (n)</td>
<td>14.2 (1)</td>
<td>4.1 (2)</td>
<td></td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>6.4±1.1</td>
<td>5.8±0.8</td>
<td>0.08&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>282±87.1</td>
<td>224±39.4</td>
<td>0.07&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>198.9±83.7</td>
<td>140.9±39.3</td>
<td>0.06&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>50.8±15.8</td>
<td>56.8±13.0</td>
<td>0.41&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>LDL-C/HDL-C ratio</td>
<td>4.4±2.3</td>
<td>2.6±1.0</td>
<td>0.05&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Duration of statin (years)</td>
<td>4.9±6.4</td>
<td>6.3±6.3</td>
<td>0.51&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Carotid echo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMT&lt;sub&gt;max&lt;/sub&gt; (mm)</td>
<td>1.0±0.3</td>
<td>0.8±0.1</td>
<td>0.009&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>IMT&lt;sub&gt;mean&lt;/sub&gt; (mm)</td>
<td>2.8±1.2</td>
<td>1.4±0.8</td>
<td>0.007&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Plaque score</td>
<td>9.2±5.2</td>
<td>3.1±3.6</td>
<td>0.005&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CAVI</td>
<td>8.8±1.3</td>
<td>8.8±1.2</td>
<td>0.96&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Notes: Values are expressed as mean ± SD or % (n). *Mann–Whitney U test (qualitative variables were compared using an exact model). <sup>a</sup>Welch’s t-test.

Abbreviations: CAS, coronary artery stenosis; BMI, body mass index; CAD, coronary artery disease; HbA1c, hemoglobin A1c; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; CAVI, cardio-ankle vascular index.
Multiple regression analysis of various parameters for CAS
To investigate the impact of carotid arterial findings (mean IMT, max IMT, and PS), we performed multiple regression analysis, including CAVI, age, sex, and duration of statin therapy. Mean IMT and PS were selected as independent risk factors for CAS (Table 4).

Discussion
In the present study enrolling 31 asymptomatic FH patients, CAS was observed in 22.6% of patients; noncalcified plaque was observed in 29.0% of patients and calcified plaque was observed in 61.3% of patients. The incidence of CAS was similar to that of a previous report. Since FH is known to be associated with coronary events even in younger patients, the high incidence of CAS in FH patients should not be overlooked. We consider that FH patients should be monitored for CAS via less-invasive methods such as CCTA, even when they have no symptoms.

In patients with CAS, the proportions of male patients and mean LDL-cholesterol level were higher than in non-CAS patients, suggesting that these factors may be associated with the incidence of CAS in FH patients. The proportions of patients who had concomitant diabetes mellitus (57.1%) and hypertension (57.1%) were higher in the CAS group than in non-CAS patients (29.2% and 20.8%, respectively). The difference was not significant. But, controlling these risk factors may be important in FH patients.
We also compared the findings from ultrasonography of the carotid artery and CAVI in terms of predictive ability of CAS in FH patients. As shown in Table 3, the carotid parameters measured by ultrasonography (ie, mean IMT, maximum IMT, and PS) were significantly higher in CAS patients than in non-CAS patients, suggesting that the presence of carotid plaque may be a predictor of coronary atherosclerosis in asymptomatic FH patients. Since the PS showed the most marked difference among the carotid parameters measured in the present study (Table 4), it may be a useful index for the prediction of CAS in asymptomatic FH patients.

CAVI was not significantly different between patients with and without CAS. This was consistent with the findings from the previous by Soska et al. They compared CAVI in FH patients and in healthy controls. There was no significant difference in HDL-cholesterol levels between FH patients and the controls. In our study, there was also no significant difference in HDL-cholesterol levels between patients with and without CAS, although LDL-cholesterol level was higher in patients with CAS. On the other hand, another study showed that a significant increase in CAVI was observed in patients with combined hyperlipidemia who had a low (<40 mg/dL) HDL-cholesterol level but not in patients with hypercholesterolemia alone. These findings suggested that CAVI may increase when both increased LDL-cholesterol level and decreased HDL-cholesterol level were observed.

Another possible explanation as to why no increase in CAVI was observed in CAS patients may be attributed to the developmental process of atherosclerosis in FH patients. We consider that FH patients may have a different developmental process of wall thickening from those with atherosclerosis, caused by hypertension, obesity, and diabetes. Atherosclerosis develops through several processes of fatty streak, fibrous plaque, atheroma formation, and complicated lesion. When the fatty streak was formed cholesterol ester deposited. Afterward calcification and/or inflammation occur at the fibrous plaque to complicated lesion stages. In a study that measured aortic PWV in rabbits, aortic stiffness was not enhanced in hypercholesterolemia. Therefore, in FH patients, an increase in CAVI may not be prominent at the fatty streak stage when calcification and inflammatory processes have not been established. However, CAVI may be increasing when calcification and inflammatory processes have started. In fact, increased CAVI was observed in FH patients who had developed severe coronary stenosis, and underwent angioplasty (data not shown). Therefore, in clinical practice, even when CAVI shows normal in FH patients, coronary artery disease cannot be denied. We consider that FH patients should be continuously monitored with CCTA and ultrasonography.

**Limitations**

Although FH is not a common disease, the sample size of the present study was small. Nevertheless, a statistical significance was obtained for some parameters for the prediction of CAS in asymptomatic FH patients. We consider the findings are important and useful in clinical practice.

**Conclusion**

Although the sample size limits the ability to draw conclusions, in this study of asymptomatic FH patients, CAS was identified in 22.6% of patients by CCTA. An increase in CAVI was not observed in patients with CAS; however, the possibility of coronary artery disease cannot be ruled out, and FH patients should be continuously monitored with CCTA and ultrasonography.

**Acknowledgments**

We wish to thank the members of the Clinical Physiology Unit for the measurement of CAVI and also the members of the Radiological Department for examination of MSCT. The Department of Vascular Function was funded by Fukuda Denshi CO., Ltd.

---

**Table 4 Significance of risk factors for CAS by multiple regression analysis**

<table>
<thead>
<tr>
<th>Model 1</th>
<th>B</th>
<th>t-value</th>
<th>P-value</th>
<th>Model 2</th>
<th>B</th>
<th>t-value</th>
<th>P-value</th>
<th>Model 3</th>
<th>B</th>
<th>t-value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.01</td>
<td>-1.09</td>
<td>0.77</td>
<td>Age</td>
<td>0.01</td>
<td>-0.12</td>
<td>0.90</td>
<td>Age</td>
<td>0.01</td>
<td>-0.44</td>
<td>0.89</td>
</tr>
<tr>
<td>Sex</td>
<td>0.15</td>
<td>2.54</td>
<td>0.02</td>
<td>Sex</td>
<td>0.16</td>
<td>1.87</td>
<td>0.07</td>
<td>Sex</td>
<td>0.15</td>
<td>2.37</td>
<td>0.02</td>
</tr>
<tr>
<td>Duration of statin</td>
<td>0.01</td>
<td>-0.89</td>
<td>0.38</td>
<td>Duration of statin</td>
<td>0.01</td>
<td>-0.58</td>
<td>0.56</td>
<td>Duration of statin</td>
<td>0.01</td>
<td>-0.54</td>
<td>0.59</td>
</tr>
<tr>
<td>Mean IMT</td>
<td>0.33</td>
<td>2.27</td>
<td>0.03</td>
<td>Maximum IMT</td>
<td>0.07</td>
<td>1.94</td>
<td>0.06</td>
<td>PS</td>
<td>0.02</td>
<td>2.42</td>
<td>0.02</td>
</tr>
<tr>
<td>CAVI</td>
<td>0.06</td>
<td>0.02</td>
<td>0.99</td>
<td>CAVI</td>
<td>0.06</td>
<td>0.12</td>
<td>0.91</td>
<td>CAVI</td>
<td>0.06</td>
<td>0.48</td>
<td>0.64</td>
</tr>
</tbody>
</table>

Notes: \( \beta \) indicates a slope coefficient. The t-values were calculated by the following equation: \( \beta / \text{standard error of } \beta \). Each model included one of the three carotid ultrasonography parameters to determine which parameter is most associated with CAS.

Abbreviations: CAS, coronary artery stenosis; IMT, intima-media thickness; PS, plaque score; CAVI, cardio-ankle vascular index.
Disclosure

The authors report no conflicts of interest in this work.

References